Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ned Pethick is active.

Publication


Featured researches published by Ned Pethick.


Advances in Therapy | 2004

Psychometric validation of a patient-reported sensory perception and preference instrument: the Sensory Perceptions Questionnaire.

Richard D. Lennox; Ivy Fowler; Mugdha Gore; M. Kathryn C. Jones; Ned Pethick; Liza O’Dowd

This study evaluated the psychometric properties of content validity, construct validity, and test-retest reliability of a 23-item Sensory Perceptions Questionnaire (SPQ) used to survey sensory perceptions of intranasal corticosteroid sprays. Two patient cohorts (men and women aged ≥18 years who had at least a 1-year history of allergic rhinitis and had been using a corticosteroid nasal spray) were enrolled. The content validity and construct validity of the SPQ questions were evaluated using a cognitive debriefing method after cohort 1 (n=15) completed the SPQ. Test-retest reliability (assessed with intraclass correlation coefficients [ICCs] of the SPQ questions) was evaluated in cohort 2 (n=50), after they answered a Web-based version of the SPQ on two occasions, each separated by 7 days. In cohort 1, 7 of 15 patients believed all relevant sensory perceptions were addressed in the questionnaire. Although 8 patients mentioned at least 1 sensory perception that was not addressed, only 4 sensory perceptions were mentioned by more than 1 patient, and none was mentioned reliably by more than 2 patients. Those 4 sensory perceptions not addressed in the SPQ were all intentionally excluded, because they were potential symptoms of rhinitis or adverse events associated with intranasal corticosteroid spray use. Patients regarded the questions as straightforward, nonburdensome, and nonthreatening, signs suggesting the questions were not likely to challenge the construct validity of the SPQ. The responses to 2 questions (one in which patients were asked to indicate whether they were pleased or displeased overall with a particular spray; the other to indicate their overall product preference) were somewhat influenced by the effectiveness of the sprays. Results of test-retest reliability (cohort 2) showed both high (>0.8) and low (<0.7) ICCs. A high degree of correspondence between the 2 administrations produced a low between-patient variance, which likely resulted in lower ICCs. The SPQ adequately represents the sensory attributes reported by patients regarding intranasal corticosteroid spray use and, overall, is a valid measure of patient preference based on sensory perception.


The Journal of Allergy and Clinical Immunology: In Practice | 2014

Comparative Effectiveness of Budesonide-Formoterol Combination and Fluticasone-Salmeterol Combination for Asthma Management: A United States Retrospective Database Analysis

Ozgur Tunceli; Setareh A. Williams; David M. Kern; Hanaa Elhefni; Ned Pethick; Catrin Wessman; Siting Zhou; Frank Trudo

BACKGROUND Comparative effectiveness of the budesonide-formoterol fumarate dihydrate combination (BFC) and the fluticasone propionate-salmeterol combination (FSC) therapy on asthma exacerbation has not been assessed in real-world settings in the United States. OBJECTIVE To compare exacerbation rates and health care utilization for patients with asthma who initiate BFC versus FSC therapy. METHODS This retrospective cohort comparative effectiveness study queried medical and pharmacy data for patients with asthma from a large managed care data repository that covers major US population centers. The patients were 12 to 64 years old, with ≥12 months of pre- and postindex enrollment and ≥1 pharmacy claim(s) for BFC or FSC initiated during June 1, 2007, and September 30, 2010; the first prescription fill date was defined as the index date. Patients with other respiratory diseases and/or cancer were excluded. Exacerbation was defined as asthma-related hospitalization, emergency department visit, and/or oral corticosteroid prescription fill. Cohorts were matched by using propensity scores. RESULTS A total of 3043 patients per cohort were matched and balanced. During the 12 months following the initiation the BFC cohort had lower adjusted exacerbations per person year versus the FSC cohort (0.85 vs 0.93; RR 0.92, 95% CI [0.85-0.99]), lower oral corticosteroid fill rates, and fewer asthma-related emergency department visits but comparable asthma-related hospitalization. CONCLUSIONS Asthma exacerbation was lower for BFC versus FSC initiators due to lower rates of oral corticosteroid use and asthma-related emergency department visits, which indicate better treatment effectiveness of those patients initiated with BFC compared with FSC.


International Journal of Chronic Obstructive Pulmonary Disease | 2014

A US database study characterizing patients initiating a budesonide–formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease

David M. Kern; Setareh A. Williams; Ozgur Tunceli; Catrin Wessman; Siting Zhou; Ned Pethick; Hanaa Elhefni; Frank Trudo

Objective To compare clinical and demographic characteristics, resource utilization and costs of chronic obstructive pulmonary disease (COPD) patients prior to initiating budesonide–formoterol combination (BFC) or tiotropium-maintenance therapy. Materials and methods This cross-sectional study used claims-based diagnosis to identify COPD patients in the HealthCore Integrated Research Database who initiated BFC or tiotropium therapy between March 1, 2009 and January 31, 2012 (intake period); the index date was defined as the initial prescription fill for either agent. Patients diagnosed with respiratory tract cancer or receiving inhaled corticosteroids/long-acting β2-adrenergic agonists or tiotropium in 12 months prior to index date were excluded. Categorical variables were evaluated with χ2 tests; mean cost differences were evaluated using γ-regression. Results Overall, 6,940 BFC and 10,831 tiotropium patients were identified. The BFC group was younger (mean age 64 versus 67 years), with a greater proportion of females (54% versus 51%). BFC-treated patients had more comorbid respiratory conditions, including asthma (25% versus 13%), but fewer comorbid cardiovascular conditions, including atherosclerosis (7% versus 10%) and myocardial infarction (4% versus 6%). A greater proportion of BFC patients received prior respiratory medication, including oral corticosteroids (46% versus 35%) and short-acting β2-agonists (44% versus 35%). Tiotropium-treated patients had a greater mean number of COPD-related outpatient visits (4.6 versus 4.1). BFC-treated patients had lower total all-cause (


Clinical Therapeutics | 2003

Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray

Shailen Shah; Christopher J. Miller; Ned Pethick; Thomas Uryniak; M. Kathryn C. Jones; L. O'Dowd

17,259 versus


Value in Health | 2005

Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective

Joshua S. Benner; Timothy W. Smith; David Klingman; Jonothan C. Tierce; C. Daniel Mullins; Ned Pethick; John C. O'Donnell

17,926) and COPD-related (


Value in Health | 2004

PCV18 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN

Joshua S. Benner; Timothy W. Smith; David Klingman; Jonothan C. Tierce; Cd Mullins; Ned Pethick; John C. O'Donnell

1,718 versus


The Journal of Allergy and Clinical Immunology | 2003

Psychometric validation of a patient-based preference instrument: The sensory perceptions questionnaire (SPQ)*

R.D. Lonnox; I. Fowler; M. Gore; K.C. Jones; Ned Pethick; L. O'Dowd

1,930) health care costs, driven by lower all-cause and COPD-related inpatient expenditures. Conclusion Initiators of BFC or tiotropium showed differences in clinical and demographic characteristics and health care utilization and costs prior to starting COPD maintenance therapy.


The Journal of Allergy and Clinical Immunology | 2002

Patients with allergic rhinitis prefer budesonide aqueous nasal spray to fluticasone propionate nasal spray based on sensory attributes

S.R. Shah; Christopher J. Miller; Ned Pethick; L. O'Dowd


The American Journal of Managed Care | 2014

Initiation of Inhaled Corticosteroid and Long-Acting b2-adrenergic Agonist (ICS/LABA) in Asthma

Ozgur Tunceli; David M. Kern; Setareh A. Williams; Ned Pethick; Ma Lisa Suchower


The Journal of Allergy and Clinical Immunology | 2013

Comparative Effectiveness of Budesonide/Formoterol Combination (BFC) and Fluticasone/Salmeterol Combination (FSC) Among Asthma Patients

Setareh A. Williams; Ozgur Tunceli; David M. Kern; Ned Pethick; Hanaa Elhefni; Catrin Wessman; Siting Zhou; Frank Trudo

Collaboration


Dive into the Ned Pethick's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joshua S. Benner

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge